Table 2.

Major atrial fibrillation stroke prevention trials

Study	Patient population	Comparator groups	Stroke or systemic embolism	Major hemorrhage
RE-LY (open label)	Mean age 71 years Mean CHADS2 2.1 Mean TTR 64% History of Stroke or TIA 20%	Dabigatran 150 mg Dabigatran 110 mg Warfarin	Dabigatran 150 vs. warfarin: RR 0.66 95% CI 0.53–0.82 Dabigatran 110 vs. warfarin: RR 0.91 95% CI 0.74–1.11	Dabigatran 150 vs. warfarin: RR 0.93 95% CI 0.81–1.07 Dabigatran 110 vs. warfarin: RR 0.80 95% CI 0.69–0.93
ROCKET-AF (Randomized controlled)	Mean age 73 years Mean CHADS2 3.5 Mean TTR 55% History of Stroke, systemic embolism or TIA 55%	Rivaroxaban 20 mg Warfarin	HR 0.88 95% CI 0.75–1.03	HR 0.69 95% CI 0.90–1.20
ARISTOTLE (Randomized controlled)	Mean age 70 years Mean CHADS2 2.1 Mean TTR 62% History of Stroke	Apixaban 5 mg Warfarin	HR 0.79 95% CI 0.66–0.95	HR 0.69 95% CI 0.60–0.80
ENGAGE (Randomized controlled)	Median age 72 years Mean CHADS2 2.8 Median TTR 68% History of Stroke or TIA 28%	Edoxaban 60 mg Edoxaban 30 mg Warfarin	Edoxaban 60 vs. warfarin: HR 0.79 95% CI 0.63–0.99 Edoxaban 30 vs. warfarin: HR 1.07 95% CI 0.87–1.31	Edoxaban 60 vs. warfarin: HR 0.80 95% CI 0.71–0.91 Edoxaban 30 vs. warfarin: HR 0.47 95% CI 0.41–0.55
AVEROES (Randomized controlled)	Mean age 70 years Mean CHADS2 2.0 History of Stroke or TIA 14%	Apixaban 5 mg Aspirin 81–324 mg	HR 0.45 95% CI 032–0.62	HR 1.13 95% CI 0.74–1.75
PREVAIL-AF and PROTECT-AF – 5 year follow up	Mean age 73 years Mean CHADS2 2.3 Mean TTR 62% History of Stroke or TIA 23%	WATCHMAN Warfarin	HR 0.96 95% 0CI 0.60–1.54	HR 0.91 95% CI 0.64–1.29 (Including procedural bleeding) HR 0.48 95% CI 0.32–0.71 (Excluding procedural bleeding)